Dapagliflozin
- Generic Name
- Dapagliflozin
- Brand Names
- Edistride, Farxiga, Forxiga, Qtern, Qternmet, Xigduo, Dapagliflozin Viatris
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25ClO6
- CAS Number
- 461432-26-8
- Unique Ingredient Identifier
- 1ULL0QJ8UC
- Background
Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tubule of the nephron and causing glycosur...
- Indication
Dapagliflozin is indicated as an adjunct treatment to improve glycemic control in adult patients with type 2 diabetes mellitus along with diet and exercise.For patients with chronic kidney disease at risk of progression, dapagliflozin in used to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and
...
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate, Hospitalization due to cardiac failure
- Associated Therapies
- -
The Effect of Short-term Insulin Intensive Therapy Based on the Application of Insulin Pump and Real-time Dynamic Glucose Monitoring Technology on Reversing the Newly Diagnosed Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 210
- Registration Number
- NCT06127433
- Locations
- 🇨🇳
刘烈华, Guandong, China
Sodium-Glucose Cotransporter-2 Inhibitor for Acute Cardiorenal Syndrome: A Feasibility Study
- First Posted Date
- 2023-11-01
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- Yale University
- Target Recruit Count
- 60
- Registration Number
- NCT06111768
- Locations
- 🇺🇸
Yale New Haven Hospital, New Haven, Connecticut, United States
Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)
- Conditions
- Interventions
- First Posted Date
- 2023-10-18
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1760
- Registration Number
- NCT06087835
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Short and Intermediate Term Effect of Dapagliflozin on Left Ventricular Remodeling in Anterior STEMI Patients
- First Posted Date
- 2023-07-24
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Mohamed Nabil Elkholy
- Target Recruit Count
- 120
- Registration Number
- NCT05957887
- Locations
- 🇪🇬
Helwan University, Cairo, Egypt
Phase 3 Clinical Trial with Dapagliflozin in Chronic Kidney Disease in Adolescents and Young Adult Patients
- Conditions
- Interventions
- First Posted Date
- 2023-07-13
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- University Hospital Goettingen
- Target Recruit Count
- 102
- Registration Number
- NCT05944016
- Locations
- 🇩🇪
Universitätsklinikum Heidelberg - Children, Heidelberg, Baden-Württenberg, Germany
🇩🇪LMU Klinikum, München, Bayern, Germany
🇩🇪v. Haunersches Kinderhospital, München, Bayern, Germany
Efficacy and Safety of LID104 in the Treatment of Type II Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2023-06-02
- Last Posted Date
- 2023-06-02
- Lead Sponsor
- EMS
- Target Recruit Count
- 597
- Registration Number
- NCT05886088
- Locations
- 🇧🇷
Investigational site, Hortolândia, SP, Brazil
Dapagliflozin Effect on FunctiOnal Mitral Regurgitation and Myocardial Fibrosis (DEFORM)
- First Posted Date
- 2023-05-08
- Last Posted Date
- 2023-05-08
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 166
- Registration Number
- NCT05848102
- Locations
- 🇨🇳
The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China
🇨🇳The Second Affiliated Hospital of Guangzhou Medical University, Guanzhou, Guangdong, China
🇨🇳The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China
Dapagliflozin in Non Alcoholic Fatty Liver Disease Associated Cirrhosis and Its Role in Preventing Development of Chronic Kidney Disease.
- Conditions
- Interventions
- First Posted Date
- 2023-05-08
- Last Posted Date
- 2023-05-08
- Lead Sponsor
- Institute of Liver and Biliary Sciences, India
- Target Recruit Count
- 144
- Registration Number
- NCT05849220
- Locations
- 🇮🇳
Institute of Liver & Biliary Sciences, New Delhi, Delhi, India
Dapagliflozin Evaluation on Atrial Fibrillation Patients Followed Cox Maze IV Procedure
- Conditions
- Interventions
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- Kun Hua
- Target Recruit Count
- 348
- Registration Number
- NCT05816733
- Locations
- 🇨🇳
Cardiac Surgery Center No. 7, Beijing, Beijing, China
Dapa Acute Heart Failure Study
- Conditions
- First Posted Date
- 2023-03-08
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- Chinese University of Hong Kong
- Target Recruit Count
- 100
- Registration Number
- NCT05759000
- Locations
- 🇭🇰
The Chinese University of Hong Kong, Shatin, Hong Kong
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.